Nanopublications LDF server

Matches in Nanopublications for { ?s ?p "[Altogether, our data suggest that AMPK is an attractive target for the treatment of BCR-ABL-expressing malignancies and raise the potential for use of AMPK activators in the treatment of refractory chronic myeloid leukemia and Ph(+) acute lymphoblastic leukemia.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine."@en ?g. }

• assertion description "[Altogether, our data suggest that AMPK is an attractive target for the treatment of BCR-ABL-expressing malignancies and raise the potential for use of AMPK activators in the treatment of refractory chronic myeloid leukemia and Ph(+) acute lymphoblastic leukemia.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
• assertion description "[Altogether, our data suggest that AMPK is an attractive target for the treatment of BCR-ABL-expressing malignancies and raise the potential for use of AMPK activators in the treatment of refractory chronic myeloid leukemia and Ph(+) acute lymphoblastic leukemia.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
• assertion description "[Altogether, our data suggest that AMPK is an attractive target for the treatment of BCR-ABL-expressing malignancies and raise the potential for use of AMPK activators in the treatment of refractory chronic myeloid leukemia and Ph(+) acute lymphoblastic leukemia.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
• NP668267.RAAjer3E8VKDk_96_CHoQg-CQq5lyuhjKwk31riPFcNrQ130_assertion description "[Altogether, our data suggest that AMPK is an attractive target for the treatment of BCR-ABL-expressing malignancies and raise the potential for use of AMPK activators in the treatment of refractory chronic myeloid leukemia and Ph(+) acute lymphoblastic leukemia.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP668267.RAAjer3E8VKDk_96_CHoQg-CQq5lyuhjKwk31riPFcNrQ130_provenance.
• NP373390.RAms2j-9Muefp9uirhr6Bxt0EhnKR07sWdFzQ1hqo65JQ130_assertion description "[Altogether, our data suggest that AMPK is an attractive target for the treatment of BCR-ABL-expressing malignancies and raise the potential for use of AMPK activators in the treatment of refractory chronic myeloid leukemia and Ph(+) acute lymphoblastic leukemia.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP373390.RAms2j-9Muefp9uirhr6Bxt0EhnKR07sWdFzQ1hqo65JQ130_provenance.
• NP506859.RAXlQfAdkFvBPHblFT_zDFbkVEkSuyyffxeRTp6wrMSGM130_assertion description "[Altogether, our data suggest that AMPK is an attractive target for the treatment of BCR-ABL-expressing malignancies and raise the potential for use of AMPK activators in the treatment of refractory chronic myeloid leukemia and Ph(+) acute lymphoblastic leukemia.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP506859.RAXlQfAdkFvBPHblFT_zDFbkVEkSuyyffxeRTp6wrMSGM130_provenance.
• NP675791.RAZQuhd_FOKexSFwxib63oo7vIRUEaWy1JSFZmYbOk-Fo130_assertion description "[Altogether, our data suggest that AMPK is an attractive target for the treatment of BCR-ABL-expressing malignancies and raise the potential for use of AMPK activators in the treatment of refractory chronic myeloid leukemia and Ph(+) acute lymphoblastic leukemia.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP675791.RAZQuhd_FOKexSFwxib63oo7vIRUEaWy1JSFZmYbOk-Fo130_provenance.
• NP737580.RAe6VjJPICcuy1uQR4o76Uv7UWULlchCTNpmZ6Mmm0Y1k130_assertion description "[Altogether, our data suggest that AMPK is an attractive target for the treatment of BCR-ABL-expressing malignancies and raise the potential for use of AMPK activators in the treatment of refractory chronic myeloid leukemia and Ph(+) acute lymphoblastic leukemia.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP737580.RAe6VjJPICcuy1uQR4o76Uv7UWULlchCTNpmZ6Mmm0Y1k130_provenance.
• NP773257.RAVFIPOXs5aSYIvaBO1LAJbSpGwmLknPavNOcJh4glRsI130_assertion description "[Altogether, our data suggest that AMPK is an attractive target for the treatment of BCR-ABL-expressing malignancies and raise the potential for use of AMPK activators in the treatment of refractory chronic myeloid leukemia and Ph(+) acute lymphoblastic leukemia.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP773257.RAVFIPOXs5aSYIvaBO1LAJbSpGwmLknPavNOcJh4glRsI130_provenance.
• NP899042.RAzoo9Ck3RIYysdVK9dH03DYp1ywPnjyqpyzsouKa3OfI130_assertion description "[Altogether, our data suggest that AMPK is an attractive target for the treatment of BCR-ABL-expressing malignancies and raise the potential for use of AMPK activators in the treatment of refractory chronic myeloid leukemia and Ph(+) acute lymphoblastic leukemia.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP899042.RAzoo9Ck3RIYysdVK9dH03DYp1ywPnjyqpyzsouKa3OfI130_provenance.
• NP744937.RA_FZD2pkr_Wl6kOig3jhFUTIyYHDdhAKXXrjPTIDwMqA130_assertion description "[Altogether, our data suggest that AMPK is an attractive target for the treatment of BCR-ABL-expressing malignancies and raise the potential for use of AMPK activators in the treatment of refractory chronic myeloid leukemia and Ph(+) acute lymphoblastic leukemia.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP744937.RA_FZD2pkr_Wl6kOig3jhFUTIyYHDdhAKXXrjPTIDwMqA130_provenance.
• NP641956.RAQsfNZx1Bf5EJm5rtN8D9W4CAoBNCrPgH30eZqfXg-IU130_assertion description "[Altogether, our data suggest that AMPK is an attractive target for the treatment of BCR-ABL-expressing malignancies and raise the potential for use of AMPK activators in the treatment of refractory chronic myeloid leukemia and Ph(+) acute lymphoblastic leukemia.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP641956.RAQsfNZx1Bf5EJm5rtN8D9W4CAoBNCrPgH30eZqfXg-IU130_provenance.
• NP828181.RAxY7o6_GN12bJe_yEGNDkVo1P5YOxaL8Dq29caDIesiU130_assertion description "[Altogether, our data suggest that AMPK is an attractive target for the treatment of BCR-ABL-expressing malignancies and raise the potential for use of AMPK activators in the treatment of refractory chronic myeloid leukemia and Ph(+) acute lymphoblastic leukemia.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP828181.RAxY7o6_GN12bJe_yEGNDkVo1P5YOxaL8Dq29caDIesiU130_provenance.
• assertion description "[Altogether, our data suggest that AMPK is an attractive target for the treatment of BCR-ABL-expressing malignancies and raise the potential for use of AMPK activators in the treatment of refractory chronic myeloid leukemia and Ph(+) acute lymphoblastic leukemia.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
• assertion description "[Altogether, our data suggest that AMPK is an attractive target for the treatment of BCR-ABL-expressing malignancies and raise the potential for use of AMPK activators in the treatment of refractory chronic myeloid leukemia and Ph(+) acute lymphoblastic leukemia.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
• assertion description "[Altogether, our data suggest that AMPK is an attractive target for the treatment of BCR-ABL-expressing malignancies and raise the potential for use of AMPK activators in the treatment of refractory chronic myeloid leukemia and Ph(+) acute lymphoblastic leukemia.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
• assertion description "[Altogether, our data suggest that AMPK is an attractive target for the treatment of BCR-ABL-expressing malignancies and raise the potential for use of AMPK activators in the treatment of refractory chronic myeloid leukemia and Ph(+) acute lymphoblastic leukemia.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
• assertion description "[Altogether, our data suggest that AMPK is an attractive target for the treatment of BCR-ABL-expressing malignancies and raise the potential for use of AMPK activators in the treatment of refractory chronic myeloid leukemia and Ph(+) acute lymphoblastic leukemia.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
• assertion description "[Altogether, our data suggest that AMPK is an attractive target for the treatment of BCR-ABL-expressing malignancies and raise the potential for use of AMPK activators in the treatment of refractory chronic myeloid leukemia and Ph(+) acute lymphoblastic leukemia.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
• assertion description "[Altogether, our data suggest that AMPK is an attractive target for the treatment of BCR-ABL-expressing malignancies and raise the potential for use of AMPK activators in the treatment of refractory chronic myeloid leukemia and Ph(+) acute lymphoblastic leukemia.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
• assertion description "[Altogether, our data suggest that AMPK is an attractive target for the treatment of BCR-ABL-expressing malignancies and raise the potential for use of AMPK activators in the treatment of refractory chronic myeloid leukemia and Ph(+) acute lymphoblastic leukemia.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
• assertion description "[Altogether, our data suggest that AMPK is an attractive target for the treatment of BCR-ABL-expressing malignancies and raise the potential for use of AMPK activators in the treatment of refractory chronic myeloid leukemia and Ph(+) acute lymphoblastic leukemia.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
• NP933107.RAeQo_EKT1-MVjffy7caPrBxATXFlvXNPBjIKTxVyTwcc130_assertion description "[Altogether, our data suggest that AMPK is an attractive target for the treatment of BCR-ABL-expressing malignancies and raise the potential for use of AMPK activators in the treatment of refractory chronic myeloid leukemia and Ph(+) acute lymphoblastic leukemia.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP933107.RAeQo_EKT1-MVjffy7caPrBxATXFlvXNPBjIKTxVyTwcc130_provenance.
• NP933114.RAS17f0ClzBt1pYjFEzE6dsxB6jhwsoPQ-eAKyzvSf7N8130_assertion description "[Altogether, our data suggest that AMPK is an attractive target for the treatment of BCR-ABL-expressing malignancies and raise the potential for use of AMPK activators in the treatment of refractory chronic myeloid leukemia and Ph(+) acute lymphoblastic leukemia.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP933114.RAS17f0ClzBt1pYjFEzE6dsxB6jhwsoPQ-eAKyzvSf7N8130_provenance.
• NP933116.RAaid1U0YpKtBdIMYdMfriNqphwgqVX84j_kRJquW5Zg0130_assertion description "[Altogether, our data suggest that AMPK is an attractive target for the treatment of BCR-ABL-expressing malignancies and raise the potential for use of AMPK activators in the treatment of refractory chronic myeloid leukemia and Ph(+) acute lymphoblastic leukemia.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP933116.RAaid1U0YpKtBdIMYdMfriNqphwgqVX84j_kRJquW5Zg0130_provenance.
• NP933119.RAQPVvqSkqlMQeb_60BLBlnZTOr0Ny1tCv5vWdqjK7YG4130_assertion description "[Altogether, our data suggest that AMPK is an attractive target for the treatment of BCR-ABL-expressing malignancies and raise the potential for use of AMPK activators in the treatment of refractory chronic myeloid leukemia and Ph(+) acute lymphoblastic leukemia.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP933119.RAQPVvqSkqlMQeb_60BLBlnZTOr0Ny1tCv5vWdqjK7YG4130_provenance.
• NP641880.RAAixEYcsWhAM4jBHlT_ZmjpuVNbb8mPB5p1vGu47rXIw130_assertion description "[Altogether, our data suggest that AMPK is an attractive target for the treatment of BCR-ABL-expressing malignancies and raise the potential for use of AMPK activators in the treatment of refractory chronic myeloid leukemia and Ph(+) acute lymphoblastic leukemia.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP641880.RAAixEYcsWhAM4jBHlT_ZmjpuVNbb8mPB5p1vGu47rXIw130_provenance.
• NP219593.RArROk0ER9lWGzsQM2an_NLKP6SnvUlrwmCmXszxgGVM4130_assertion description "[Altogether, our data suggest that AMPK is an attractive target for the treatment of BCR-ABL-expressing malignancies and raise the potential for use of AMPK activators in the treatment of refractory chronic myeloid leukemia and Ph(+) acute lymphoblastic leukemia.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP219593.RArROk0ER9lWGzsQM2an_NLKP6SnvUlrwmCmXszxgGVM4130_provenance.
• NP933118.RAD2iI2JTQTDTAR92O0Ui10cLVDQniQ2cth7ly1Af1uGo130_assertion description "[Altogether, our data suggest that AMPK is an attractive target for the treatment of BCR-ABL-expressing malignancies and raise the potential for use of AMPK activators in the treatment of refractory chronic myeloid leukemia and Ph(+) acute lymphoblastic leukemia.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP933118.RAD2iI2JTQTDTAR92O0Ui10cLVDQniQ2cth7ly1Af1uGo130_provenance.
• NP641825.RAg3uHgEeFHoipmN5FHpwRaFTlgISZC4CBYlrUDc3kBcE130_assertion description "[Altogether, our data suggest that AMPK is an attractive target for the treatment of BCR-ABL-expressing malignancies and raise the potential for use of AMPK activators in the treatment of refractory chronic myeloid leukemia and Ph(+) acute lymphoblastic leukemia.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP641825.RAg3uHgEeFHoipmN5FHpwRaFTlgISZC4CBYlrUDc3kBcE130_provenance.
• NP641952.RAl9_5VCJqB2sM4POMnh34dnq7x9cUSdGt4RLEDSqsHTM130_assertion description "[Altogether, our data suggest that AMPK is an attractive target for the treatment of BCR-ABL-expressing malignancies and raise the potential for use of AMPK activators in the treatment of refractory chronic myeloid leukemia and Ph(+) acute lymphoblastic leukemia.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP641952.RAl9_5VCJqB2sM4POMnh34dnq7x9cUSdGt4RLEDSqsHTM130_provenance.
• NP642079.RAugpvOKjZvb4nZvugWp6dQ0gp6YYWeNn7-JThzIhZTaM130_assertion description "[Altogether, our data suggest that AMPK is an attractive target for the treatment of BCR-ABL-expressing malignancies and raise the potential for use of AMPK activators in the treatment of refractory chronic myeloid leukemia and Ph(+) acute lymphoblastic leukemia.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP642079.RAugpvOKjZvb4nZvugWp6dQ0gp6YYWeNn7-JThzIhZTaM130_provenance.
• NP642083.RAino2PkUMBTMV5D6GRoda8tYRKgguIv3GVrQ8QfN2R-w130_assertion description "[Altogether, our data suggest that AMPK is an attractive target for the treatment of BCR-ABL-expressing malignancies and raise the potential for use of AMPK activators in the treatment of refractory chronic myeloid leukemia and Ph(+) acute lymphoblastic leukemia.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP642083.RAino2PkUMBTMV5D6GRoda8tYRKgguIv3GVrQ8QfN2R-w130_provenance.
• NP892485.RAHL9dJVu7bLB-a2BrU6i1NoPkRlXGSzVjvwnxPRN9lKo130_assertion description "[Altogether, our data suggest that AMPK is an attractive target for the treatment of BCR-ABL-expressing malignancies and raise the potential for use of AMPK activators in the treatment of refractory chronic myeloid leukemia and Ph(+) acute lymphoblastic leukemia.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP892485.RAHL9dJVu7bLB-a2BrU6i1NoPkRlXGSzVjvwnxPRN9lKo130_provenance.
• NP933110.RArycZ5Vv9JaMUal7dOmz9_dyYPQugnCbr1ZKInfOkPo8130_assertion description "[Altogether, our data suggest that AMPK is an attractive target for the treatment of BCR-ABL-expressing malignancies and raise the potential for use of AMPK activators in the treatment of refractory chronic myeloid leukemia and Ph(+) acute lymphoblastic leukemia.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP933110.RArycZ5Vv9JaMUal7dOmz9_dyYPQugnCbr1ZKInfOkPo8130_provenance.
• NP933113.RAhL-ni27sKHckZK11XMXrucPgBEJ7sKG_W6eV23uGD34130_assertion description "[Altogether, our data suggest that AMPK is an attractive target for the treatment of BCR-ABL-expressing malignancies and raise the potential for use of AMPK activators in the treatment of refractory chronic myeloid leukemia and Ph(+) acute lymphoblastic leukemia.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP933113.RAhL-ni27sKHckZK11XMXrucPgBEJ7sKG_W6eV23uGD34130_provenance.
• NP641980.RAG8HEGoupAYh5xpnTjMcOJ8yKyy_3e06XOwlFjuxcZOU130_assertion description "[Altogether, our data suggest that AMPK is an attractive target for the treatment of BCR-ABL-expressing malignancies and raise the potential for use of AMPK activators in the treatment of refractory chronic myeloid leukemia and Ph(+) acute lymphoblastic leukemia.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP641980.RAG8HEGoupAYh5xpnTjMcOJ8yKyy_3e06XOwlFjuxcZOU130_provenance.
• NP641744.RA3XLtHvvh9pqG9SWeskw5XPNNx-0neIm01dxX6TazZyU130_assertion description "[Altogether, our data suggest that AMPK is an attractive target for the treatment of BCR-ABL-expressing malignancies and raise the potential for use of AMPK activators in the treatment of refractory chronic myeloid leukemia and Ph(+) acute lymphoblastic leukemia.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP641744.RA3XLtHvvh9pqG9SWeskw5XPNNx-0neIm01dxX6TazZyU130_provenance.
• NP641820.RAz283jsnLHX1QLmkU14yJrhp7Uc3_HWfHkEMjEIxfqsQ130_assertion description "[Altogether, our data suggest that AMPK is an attractive target for the treatment of BCR-ABL-expressing malignancies and raise the potential for use of AMPK activators in the treatment of refractory chronic myeloid leukemia and Ph(+) acute lymphoblastic leukemia.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP641820.RAz283jsnLHX1QLmkU14yJrhp7Uc3_HWfHkEMjEIxfqsQ130_provenance.
• NP641845.RA1c2af7hnBGY2LW_7aj-scsAedL5AugzDVW8hpX1d8Vo130_assertion description "[Altogether, our data suggest that AMPK is an attractive target for the treatment of BCR-ABL-expressing malignancies and raise the potential for use of AMPK activators in the treatment of refractory chronic myeloid leukemia and Ph(+) acute lymphoblastic leukemia.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP641845.RA1c2af7hnBGY2LW_7aj-scsAedL5AugzDVW8hpX1d8Vo130_provenance.
• NP642015.RA89JhfcBbHgo06t4ugh1kncLJulUtsunT0CgR_CnUmfY130_assertion description "[Altogether, our data suggest that AMPK is an attractive target for the treatment of BCR-ABL-expressing malignancies and raise the potential for use of AMPK activators in the treatment of refractory chronic myeloid leukemia and Ph(+) acute lymphoblastic leukemia.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP642015.RA89JhfcBbHgo06t4ugh1kncLJulUtsunT0CgR_CnUmfY130_provenance.
• NP933109.RANewfF_DrmMisF5c-2iBg1ROExEMe_8fCElILATOJXtQ130_assertion description "[Altogether, our data suggest that AMPK is an attractive target for the treatment of BCR-ABL-expressing malignancies and raise the potential for use of AMPK activators in the treatment of refractory chronic myeloid leukemia and Ph(+) acute lymphoblastic leukemia.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP933109.RANewfF_DrmMisF5c-2iBg1ROExEMe_8fCElILATOJXtQ130_provenance.
• NP933112.RAGze66uH_M6_ONkOcxTbThfuWJDhP0J0vktiJSxwJTJc130_assertion description "[Altogether, our data suggest that AMPK is an attractive target for the treatment of BCR-ABL-expressing malignancies and raise the potential for use of AMPK activators in the treatment of refractory chronic myeloid leukemia and Ph(+) acute lymphoblastic leukemia.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP933112.RAGze66uH_M6_ONkOcxTbThfuWJDhP0J0vktiJSxwJTJc130_provenance.
• NP933111.RAwmls9SeB5w39pCN4ktlBhRhvxwcmCLIR9-xjR5914ts130_assertion description "[Altogether, our data suggest that AMPK is an attractive target for the treatment of BCR-ABL-expressing malignancies and raise the potential for use of AMPK activators in the treatment of refractory chronic myeloid leukemia and Ph(+) acute lymphoblastic leukemia.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP933111.RAwmls9SeB5w39pCN4ktlBhRhvxwcmCLIR9-xjR5914ts130_provenance.
• NP933115.RA1-Z3Xgu4D9oaLozRAu0C9_qyi9bOHnXWrHsBwcJ8oLk130_assertion description "[Altogether, our data suggest that AMPK is an attractive target for the treatment of BCR-ABL-expressing malignancies and raise the potential for use of AMPK activators in the treatment of refractory chronic myeloid leukemia and Ph(+) acute lymphoblastic leukemia.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP933115.RA1-Z3Xgu4D9oaLozRAu0C9_qyi9bOHnXWrHsBwcJ8oLk130_provenance.
• NP933117.RA9uggT0ASrM3GHSpLr9V8oJ78pRTfNIdxaB8hZDsPDxw130_assertion description "[Altogether, our data suggest that AMPK is an attractive target for the treatment of BCR-ABL-expressing malignancies and raise the potential for use of AMPK activators in the treatment of refractory chronic myeloid leukemia and Ph(+) acute lymphoblastic leukemia.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP933117.RA9uggT0ASrM3GHSpLr9V8oJ78pRTfNIdxaB8hZDsPDxw130_provenance.